Christine Butler
Overview
Explore the profile of Christine Butler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnell F, Mylod E, Donlon N, Davern M, Butler C, OConnor N, et al.
Transl Oncol
. 2025 Feb;
53:102302.
PMID: 39965288
Oesophageal adenocarcinoma (OAC) is a poor prognosis cancer with limited responses to standard of care treatments including chemotherapy and chemoradiotherapy. OAC has one of the strongest associations with obesity, its...
2.
Davern M, O Donovan C, Donlon N, Mylod E, Gaughan C, Bhardwaj A, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672174
The presence of an immunosuppressive tumour microenvironment in oesophageal adenocarcinoma (OAC) is a major contributor to poor responses. Novel treatment strategies are required to supplement current regimens and improve patient...
3.
Mylod E, OConnell F, Donlon N, Davern M, Marion C, Butler C, et al.
Sci Rep
. 2024 Feb;
14(1):4017.
PMID: 38369570
Oesophagogastric adenocarcinomas (OAC) are poor prognosis, obesity-associated cancers which may benefit from natural killer (NK) cell-based immunotherapies. Cellular immunotherapies encounter two key challenges to their success in OAC, namely recruitment...
4.
Donlon N, Davern M, Sheppard A, OConnell F, Moran B, Nugent T, et al.
World J Gastrointest Oncol
. 2023 Sep;
15(8):1349-1365.
PMID: 37663943
Background: There is an intimate crosstalk between cancer formation, dissemination, treatment response and the host immune system, with inducing tumour cell death the ultimate therapeutic goal for most anti-cancer treatments....
5.
Davern M, Gaughan C, O Connell F, Moran B, Mylod E, Sheppard A, et al.
Front Immunol
. 2023 Jun;
14:1150754.
PMID: 37359545
Introduction: This timely study assesses the immunosuppressive effects of surgery on cytotoxic Th1-like immunity and investigates if immune checkpoint blockade (ICB) can boost Th1-like immunity in the perioperative window in...
6.
OConnell F, Mylod E, Donlon N, Heeran A, Butler C, Bhardwaj A, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980567
Oesophageal adenocarcinoma (OAC) is a poor prognosis cancer with limited response rates to current treatment modalities and has a strong link to obesity. To better elucidate the role of visceral...
7.
Davern M, Bracken-Clarke D, Donlon N, Sheppard A, O Connell F, Heeran A, et al.
J Cancer Res Clin Oncol
. 2023 Feb;
149(9):6583-6599.
PMID: 36790524
Aim: Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current...
8.
Donlon N, Davern M, OConnell F, Sheppard A, Heeran A, Bhardwaj A, et al.
World J Gastroenterol
. 2022 Jul;
28(21):2302-2319.
PMID: 35800186
Background: In the contemporary era of cancer immunotherapy, an abundance of clinical and translational studies have reported radiotherapy (RT) and immunotherapies as a viable option for immunomodulation of many cancer...
9.
Davern M, Donlon N, OConnell F, Gaughan C, ODonovan C, Habash M, et al.
Cancer Immunol Immunother
. 2022 Jun;
72(1):55-71.
PMID: 35708739
Tumour acidosis contributes to cancer progression by inhibiting anti-tumour immunity. However, the effect of acidosis on anti-tumour T cell phenotypes in oesophageal adenocarcinoma (OAC) is unknown. Therefore, this study investigated...
10.
Davern M, Donlon N, O Connell F, Sheppard A, Hayes C, King R, et al.
Transl Oncol
. 2022 Apr;
20:101406.
PMID: 35366537
Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting 'cold' tumours...